Article
Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases - 1 Jan 2000
Rodrigues João Paulo Vilela, Campos Guilherme Rodrigues Fernandes, Bittar Cintia, Martinelli Ana de Lourdes Candolo, Campos Marília Silveira de Almeida, Pereira Leonardo Régis Leira, Rahal Paula, Souza Fernanda Fernandes
Abstract excerpt
The chronic hepatitis C (CHC) treatment is currently based on the use of direct-acting antivirals (DAAs), and patients infected with hepatitis C virus genotype 3 (GT3) have emerged as a more difficult-to-cure population. The NS5A inhibitor daclatasvir (DCV) and sofosbuvir (SOF), an NS5B viral polymerase inhibitor, are among the drugs that compose more effective and safer treatment regimens. The virus genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.